Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients — RELAX-AHF-EU  

Acute Heart Failure (AHF) Clinical Trial

Official title: A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

Status Terminated

Clinical Trial Summary

This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for Acute Heart Failure (AHF).

Clinical Trial Description

This study was aimed at generating clinical evidence, especially on the short term period (in-hospital and at 30 days) to complement existing and future serelaxin data sets in Acute Heart Failure (AHF). ;

Related Conditions & MeSH terms

• Acute Heart Failure (AHF)
• Heart Failure

• NCT number: NCT02064868
• Study type: Interventional
• Source: Novartis
• Status: Terminated
• Phase: Phase 3
• Start date: January 31, 2014
• Completion date: April 25, 2017